Windhover
Home
Home		 Register
Register		 Login
Log In		 Schedule
Schedule		 Information
Info		 Attending Companies
Attendees		 Contact
Contact		 Help
Help
November 17-19 2009Westin Copley PlaceBoston, MA

Why use Windhover Conferences partnering software?

Past Windhover Top 10 Candidates Signed a Total Potential value of $17 BILLION US in acquisitions and alliances. Are you missing out on potential opportunities? Don’t fall behind the curve. Register NOW!

  
Important Partnering Deadlines
Last Chance for Early Bird Rate 10/15/09
Partnering Opens (start scheduling meetings) 10/12/09
Fill Out Your Attendee/Company Profile 10/12/09
Last Chance to get your Company Profile into Conf. Materials 10/23/09
Last Chance for Discounted Rooms (rooms may sell out before this date) 10/26/09

About Partnering

Press Release - 9/22/09

Press Release - 10/13/09

Just Added
 Top Projects to Watch (Presenting Companies)

Why attend TA Partnerships 2009?

It’s the industry's most targeted, efficient, and strategic-level partnering meeting for life science companies seeking partnerships in the top therapeutic areas: oncology, cardiovascular, metabolic and neuroscience. The biggest players in these top therapeutic areas attend to make deals.

Who will you meet?

Who will you meet?

Maximize your return-on-conference investment with a new program and venue for 2009!

  • 55+ strategic presentations on how to build your R & D pipeline-both internally and externally
  • 1:1 partnering meetings throughout November 18 and 19
  • 3 FREE practical pre-conference workshops
  • 25+ strategies from pharma heads of R & D, BD, CEOs and corporate VCs
  • 11+ networking opportunities with the most senior level executives in the biopharma business
  • 40 handpicked TOP projects in 5 HOT Therapeutic Areas-Oncology, Metabolic, Cardiovascular, Neuroscience and NEW Inflammatory/Autoimmune Diseases (past nominees include Millennium, Myogen, Isis, Sirtris, BiPar and Kosan-all companies who went on to do big deals!)
  • Access hundreds of companies, projects and technologies (pre-clinical and clinical stage) which are also linked to Windhover’s Strategic Transactions, IN VIVO articles and Intelleos clinical pipeline links. View the complete history of alliances, financings and M&As

Past Top 10 Nominated Companies - Just a few samples of deal history:

Who are some of the speakers?

BEYOND THE BASICS! TA attracts THE most strategic level speakers and audience. Hear strategic decision-making rationale from the most senior level leaders in the industry:

Peter Høngaard Andersen, M.D., M.Sc. Scient.
Executive Vice President
Lundbeck Research

H. Christian Fibiger, Ph.D.
Chief Scientific Officer and SVP
Biovail Laboratories International SRL

Michael Lytton
EVP, Corporate and Business Development
Biogen Idec

David Michelson, M.D.
VP, Clinical Neuroscience and Ophthalmology
Merck Research Laboratories

J. Anthony Ware, MD
Vice President-Lilly Research Laboratories GBD Platform Leader-Diabetes/Cardiovascular/Acute Care
Eli Lilly and Company

Gary Gabrielsen
Vice President of Business Development
Astellas US LLC

Sandy Retsky
Global Business Development
Wyeth

Dr. Joern-Peter Halle
Vice President Early Stage Licensing
Portfolio Development Merck Serono

Jeff Hanke
Vice President, Cancer Research
AstraZeneca

Betsy Garofalo M.D.
Global Therapeutic Area Leader, CNS
Astellas

Jeremy Levin, M.D., Ph.D.
Senior Vice President, Strategic Transactions
Bristol-Myers Squibb

Anna Protopapas
Senior Vice President and Head, Corporate Development and Strategy
Millennium: The Takeda Oncology Company

Charles Wilson
Vice President, Global Head of Strategic Alliances
Novartis Institutes for BioMedical Research

Peter Wirth
Executive Vice President, Legal and Corporate Development
Genzyme Corporation

Dr. Susan Rohrer
Senior Director, External Science Affairs
Merck and Company

Dr JC Gutierrez-Ramos
SVP and Head, Immuno-Inflammation Centre of Excellence for Drug Discovery
Glaxosmithkline

Dr. Michele Mercuri
VP, Acting Head of the Dept. of Cardiovascular Medicine, Global Development
Daiichi Sankyo

What is TA Partnerships’ focus?

TA Partnerships covers the next generation treatments for (not limited to):

  • ACS
  • Acute HF
  • Allergic asthma
  • Allergic contact dermatitis
  • Alzheimer’s
  • AML
  • Asthma
  • Atrial Fibrilation
  • Autism
  • Autoimmune disorders
  • Bacterial infections
  • Chronic obstructive pulmonary diseas
  • CML
  • Colorectal Cancer
  • Crohn's disease
  • Cutaneous T cell lymphoma
  • Depression
  • Epilepsy
  • Exercise-induced asthma
  • Frontotemporal dementia
  • Glioblastoma
  • Haematological malignancies
  • Huntington’s
  • Immunological disorders
  • Inflammatory diseases
  • Liver transplant rejection
  • Migraine
  • MM
  • Morbid Obesity
  • Multiple sclerosis
  • Non-alcoholic steatohepatitis
  • Pancreatic Cancer
  • Peripheral T-cell lymphoma
  • Primary biliary cirrhosis
  • Psoriasis
  • Psychotic agitation
  • Renal cancer
  • Renal transplant rejection
  • Rheumatoid arthritis
  • Rheumatoid arthritis
  • Schizophrenia
  • Seasonal allergic rhinitis
  • Stroke
  • Systemic lupus erythematosus
  • Type 2 diabetes mellitus
  • Ulcerative colitis
  • Vascular Disease

 
2009 Sponsors

Global Sponsors:

Gold Industry Sponsor:

Regional Supporting Organization:

Biotecanada

Neuroscience Advisor:

NI Research

Inflammation Advisor:

Healogix

Oncology Advisor:

Campbell Alliance

Metabolic/Cardiovascular Advisor:

Defined Health

Association Sponsor:

LES

PR Sponsor:

Marketwire

Media Partner:

Current Partnering

Pharmalicensing.com

Major Supporting Publications:

Partner and Network with these Participating Companies:


Abbott Laboratories


Astellas


AstraZeneca


Bristol Myers Squibb


Daiichi Sankyo Co., Ltd


Eli Lilly & Company


Johnson & Johnson Pharmaceutical R&D


Merck & Co Inc.


Merck Serono International S.A.


Novartis


Novo Nordisk A/S


Pfizer Inc.


Purdue Pharma LP


Roche


Sanofi-Aventis


Schering-Plough Corp.


Takeda Pharmaceuticals NA


Wyeth Pharmaceuticals

What do your colleagues and competitors have to say about Therapeutic Area Partnerships?

“The efforts to identify the ‘Top 10 Products Available for Partnering’ were well done. The product opportunities were well profiled and the conference provided an excellent forum for serious partnering activity.”

“Top 10 idea is superb. They might not be the only products to fit the criteria, but hard to find any not deserving.”

“Few conferences offer such focus and insight for partnering.”

“A good opportunity to bring together a host of Business Development individuals through a common interest.”

“Good overview of opportunities in the Therapeutic Areas. Good partnering opportunities present at the meeting.”

“So efficient to focus on the specific TAs. Made my partnering meetings much more focused.”

“Great for networking and making contacts.”

“The forum delivered all it promised - I will definitely attend next year’s event.”

“Well organized, well run, good presenters and plenty of opportunities for meetings.”

“A very good opportunity to cut through the superfluous and go to the essential in a staccato of very efficient meetings.”

“A really good business partnering event allowing one to one scheduled meetings in a pleasant, relaxed conference environment.”

“A fantastic opportunity to network with new and old peers in the industry.”

“Good topics, the speakers were informative and the company presentations were interesting.”

If you attend one meeting this year, don’t waste your time picking through hundreds of irrelevant partners. Choose TA Partnerships 2009, whose pharmaceutical, biotechnology and investor attendees are the most senior-level in the business. Space is limited, so register today!

Click here to see who you will meet at TA Partnerships

Click here to view a Sample of Past Attending Companies